The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | J | Antiinfectives for systemic use | |
2 | J01 | Antibacterials for systemic use | |
3 | J01D | Other beta-lactam antibacterials | |
4 | J01DF | Monobactams |
Code | Title | |
---|---|---|
J01DF01 | Aztreonam | |
J01DF02 | Carumonam | |
J01DF51 |
Active Ingredient | Description | |
---|---|---|
Aztreonam |
Aztreonam exhibits activity in vitro against gram-negative aerobic pathogens, including P. aeruginosa. Aztreonam binds to penicillin-binding proteins of susceptible bacteria, which leads to inhibition of bacterial cell wall synthesis, followed by filamentation and cell lysis. |
|
Aztreonam and Avibactam |
Aztreonam inhibits bacterial peptidoglycan cell wall synthesis following binding to penicillin-binding proteins (PBPs), which leads to bacterial cell lysis and death. Avibactam is a non β-lactam, β-lactamase inhibitor that acts by forming a covalent adduct with the enzyme that is stable to hydrolysis. Avibactam inhibits both Ambler class A and class C β-lactamases and some class D enzymes, including extended-spectrum β-lactamases (ESBLs), Klebsiella pneumoniae carbapenemase (KPC) and OXA-48 carbapenemases, and AmpC enzymes. |
Title | Information Source | Document Type | |
---|---|---|---|
AZACTAM Powder for solution for injection or infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
CAYSTON Powder and solvent for nebuliser solution | European Medicines Agency (EU) | MPI, EU: SmPC | |
EMBLAVEO Powder for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |